Journal Article

A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome

Siper, P., Fastman, J., Buxbaum, J. D., Sandin, S., Trelles, P., Layton, C., Tang, L., Foss-Feig, J., Halpern, D., Harony-Nicolas, H., Zweifach, J., Frank, Y., Kolevzon, A.

2021

Overview

Background Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused by haploinsufficiency of the SHANK3 gene and characterized by global developmental delays, deficits in speech and motor function, and autism spectrum disorder (ASD). Monogenic causes of ASD such as PMS are well suited to investigations with novel therapeutics, as interventions can be targeted based on established genetic etiology. While preclinical studies have demonstrated that the neuropeptide oxytocin can reverse electrophysiological, attentional, and social recognition memory deficits in Shank3 -deficient rats, there have been no trials in individuals with PMS. The purpose of this study is to assess the efficacy and safety of intranasal oxytocin as a treatment for the core symptoms of ASD in a cohort of children with PMS. Methods Eighteen children aged 5–17 with PMS were enrolled. Participants were randomized to receive intranasal oxytocin or placebo (intranasal saline) and underwent treatment during a 12-week double-blind, parallel group phase, followed by a 12-week open-label extension phase during which all participants received oxytocin. Efficacy was assessed using the primary outcome of the Aberrant Behavior Checklist-Social Withdrawal (ABC-SW) subscale as well as a number of secondary outcome measures related to the core symptoms of ASD. Safety was monitored throughout the study period. Results There was no statistically significant improvement with oxytocin as compared to placebo on the ABC-SW (Mann–Whitney U  = 50, p  = 0.055), or on any secondary outcome measures, during either the double-blind or open-label phases. Oxytocin was generally well tolerated, and there were no serious adverse events. Limitations The small sample size, potential challenges with drug administration, and expectancy bias due to relying on parent reported outcome measures may all contribute to limitations in interpreting results. Conclusion Our results suggest that intranasal oxytocin is not efficacious in improving the core symptoms of ASD in children with PMS. Trial registration NCT02710084.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adolescent / ASD / Autism / Autism spectrum disorder / Autism Spectrum Disorder - genetics / Caregivers / Child / Child, Preschool / Chromosome Deletion / Chromosome Disorders - diagnosis / Chromosome Disorders - drug therapy / Chromosomes, Human, Pair 22 / Dosage and administration / Drug dosages / Drug therapy / Drug withdrawal / Gene expression / Human Genetics / Humans / Intellectual disabilities / Intranasal medication / Medicine / Medicine & Public Health / Memory / Neurodevelopmental disorders / Neurology / Neuropsychology / Neurosciences / Oxytocin / Oxytocin - therapeutic use / Pediatric research / Pediatrics / Pervasive developmental disorders / Phelan-McDermid syndrome / PMS / Psychiatry / Shank3 / Social research / Testing